Abstract
Background: It is well-known that COVID-19 causes pneumonia and acute respiratory distress syndrome, as well as pathological neuroradiological imaging findings and various neurological symptoms associated with them. These include a range of neurological diseases, such as acute cerebrovascular diseases, encephalopathy, meningitis, encephalitis, epilepsy, cerebral vein thrombosis, and polyneuropathies. Herein, we report a case of reversible intracranial cytotoxic edema due to COVID-19, who fully recovered clinically and radiologically.
Case Report: A 24-year-old male patient presented with a speech disorder and numbness in his hands and tongue, which developed after flu-like symptoms. An appearance compatible with COVID-19 pneumonia was detected in thorax computed tomography. Delta variant (L452R) was positive in the COVID reverse-transcriptase polymerase chain reaction test (RT-PCR). Cranial radiological imaging revealed intracranial cytotoxic edema, which was thought to be related to COVID-19. Apparent diffusion coefficient (ADC) measurement values in the magnetic resonance imaging (MRI) taken on admission were 228 mm2/sec in the splenium and 151 mm2/sec in the genu. During the follow-up visits of the patient, epileptic seizures developed due to intracranial cytotoxic edema. ADC measurement values in the MRI taken on the 5th day of the patient's symptoms were 232 mm2/sec in the splenium and 153 mm2/sec in the genu. ADC measurement values in the MRI taken on the 15th day were 832 mm2/sec in the splenium and 887 mm2/sec in the genu. He was discharged from the hospital on the 15th day of his complaint with a clinical and radiological complete recovery.
Conclusion: Abnormal neuroimaging findings caused by COVID-19 are quite common. Although not specific to COVID-19, cerebral cytotoxic edema is one of these neuroimaging findings. ADC measurement values are significant for planning follow-up and treatment options. Changes in ADC values in repeated measurements can guide clinicians about the development of suspected cytotoxic lesions. Therefore, clinicians should approach cases of COVID-19 with CNS involvement without extensive systemic involvement with caution.
[http://dx.doi.org/10.4274/tnd.2020.73669]
[http://dx.doi.org/10.1016/j.bbi.2020.03.031] [PMID: 32240762]
[http://dx.doi.org/10.1016/j.ejrad.2020.109393] [PMID: 33161199]
[http://dx.doi.org/10.1148/rg.2017160085] [PMID: 28165876]
[http://dx.doi.org/10.1148/radiol.2020201697] [PMID: 32384020]
[http://dx.doi.org/10.1016/j.ijid.2020.03.062] [PMID: 32251791]
[http://dx.doi.org/10.1056/NEJMc2008597] [PMID: 32294339]
[http://dx.doi.org/10.1007/s11684-020-0786-5] [PMID: 32367431]
[http://dx.doi.org/10.1111/ene.14491] [PMID: 32853434]
[http://dx.doi.org/10.1002/jmv.26207] [PMID: 32558956]
[http://dx.doi.org/10.3174/ajnr.A6713] [PMID: 32819904]
[http://dx.doi.org/10.1007/s00401-020-02166-2] [PMID: 32449057]
[http://dx.doi.org/10.1177/19714009211029177] [PMID: 34224248]
[http://dx.doi.org/10.1136/practneurol-2018-001880] [PMID: 29599175]
[http://dx.doi.org/10.1002/brb3.1440] [PMID: 31588684]
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.10.033] [PMID: 26654670]